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Objective: Evaluate implementation of misoprostol for postabortion care (MPAC) in two African countries.
Design: Qualitative, program evaluation.
Setting: Twenty-five public and private health facilities in Rift Valley Province, Kenya, and Kampala
Province, Uganda.
Sample: Forty-five MPAC providers, health facility managers, Ministry of Health officials, and non-
governmental (NGO) staff involved in program implementation.
Methods and main outcome measures: In both countries, the Ministry of Health, local health centers and
hospitals, and NGO staff developed evidence-based service delivery protocols to introduce MPAC in selected
facilities; implementation extended from January 2009 to October 2010. Semi-structured, in-depth interviews
evaluated the implementation process, identified supportive and inhibitive policies for implementation,
elicited lessons learned during the process, and assessed provider satisfaction and providers’ impressions of
client satisfaction with MPAC. Project reports were also reviewed.
Results: In both countries, MPAC was easy to use, and freed up provider time and health facility resources
traditionally necessary for provision of PAC with uterine aspiration. On-going support of providers following
training ensured high quality of care. Providers perceived that many women preferred MPAC, as they avoided
instrumentation of the uterus, hospital admission, cost, and stigma associated with abortion. Appropriate
registration of misoprostol for use in the pilot, and maintaining supplies of misoprostol, were significant
challenges to service provision. Support from the Ministry of Health was necessary for successful
implementation; lack of country-based standards and guidelines for MPAC created challenges.
Conclusions: MPAC is simple, cost-effective and can be readily implemented in settings with high rates of
abortion-related mortality.
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U
nsafe abortion and its complications are a major
health risk to women around the world, parti-
cularly in developing countries. Global data
indicate that, regardless of abortion laws, abortions occur
in measurable numbers in all regions of the world;
however, legal restrictions on abortion shift the balance
of abortion procedures from those that are legal and safe,
to those that are unsafe (1, 2). Such is the case in Eastern
Africa, where, despite restrictive abortion laws, rates of
unsafe abortion are some of the highest in the world at
36 unsafe abortions per 1,000 women aged 15 44 (3). In
Kenya and Uganda, two Eastern African countries where
abortion has been highly restricted
1 (4 6), recent esti-
mates of the maternal mortality ratio (MMR) are 530
and 430 per 100,000 live births, respectively (7). As much
as 18 35% of these deaths are attributable to unsafe
abortion (8, 9). Morbidity related to induced abortion
is similarly high in the region; the annual rate of
hospitalization for complications related to induced
abortion is 10/1,000 women (10). While striking, these
(page number not for citation purpose)
1Kenya adopted a new constitution in 2010 (6), which has reduced
restrictions on abortion. However, unsafe abortion remains a
problem in the country.
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morbidity and mortality related to unsafe abortion, given
that stigma, fear of legal reprisals, and deaths outside of
the hospital contribute to gross under-reporting of
abortion-related mortality (1).
Postabortion care (PAC) is an approach for reducing
deaths and injuries from incomplete and unsafe abortions
by removing the remaining products of conception from
the uterus and treating associated complications, such as
bleeding or infection. The PAC model also includes
provision of post-treatment family planning and links to
other needed reproductive health services and to the com-
munity (11). The World Health Organization’s (WHO)
recommended methods of uterine evacuation for PAC in
thefirsttrimesterofpregnancyareuterineaspiration,with
eitherelectric(EVA)ormanualvacuumaspirators(MVA),
or medical treatment with misoprostol (MPAC) (12).
A growing body of evidence has demonstrated that
medical treatment of incomplete abortion with misopros-
tol is an effective and acceptable alternative to vacuum
aspiration. Misoprostol, a prostaglandin-E1 analogue, is
employed for multiple obstetric and gynecologic indica-
tions, including treatment and prevention of postpartum
hemorrhage, induction of abortion and induction of
labor, among others (13 19). Misoprostol’s ability to
induce uterine contractions and soften the cervix makes it
similarly effective in emptying the uterus following
incomplete abortion (13, 20). In studies involving at least
100 women, misoprostol for incomplete abortion has
demonstrated an average efficacy of 95%, with the highest
reported success rate being 99%*rates comparable to
treatment with MVA (21 23). Because it is inexpensive,
easy to use, stable at room temperature, and can be
administered by a variety of non-parenteral routes (oral,
sublingual, buccal, and vaginal), misoprostol is well
suited for use in low-resource settings (24). Safety and
efficacy of misoprostol for treatment of incomplete
abortion due to both spontaneous abortion/miscarriage
and induced abortion have been established by a number
of studies conducted in low-resource settings, including
Tanzania (22), Mozambique (25), Burkina Faso (26), and
Uganda (23), as has women’s satisfaction with misopros-
tol for this indication (22, 23, 25, 26). A recent study
documenting the introduction of misoprostol for PAC in
Nigeria found that both women and providers were
highly satisfied with MPAC, and that integration of
misoprostol into clinical services was straightforward
and required few resources (27). WHO includes mis-
oprostol in its evidence-based guidelines and recently
added it to their Model List of Essential Medicines (28)
for medical management of incomplete abortion; mis-
oprostol had been previously included on this list
for early pregnancy termination (in combination with
mifepristone), and labor induction (29).
We sought to evaluate the implementation of MPAC
services in Kenya and Uganda. Study objectives were: (a)
to evaluate the process used to introduce MPAC in these
two countries, including barriers encountered and facil-
itating elements; (b) to assess provider satisfaction with
MPAC and provider impression of patient satisfaction
with MPAC; and (c) to identify supportive and inhibitive
policies around the use of MPAC. These data can be used
to inform future MPAC programming efforts, both those
being newly established and those ready for scaling up.
Methods
Study overview
In both countries, a baseline assessment of health
facilities participating in the project was conducted prior
to the implementation of MPAC services. During im-
plementation, site improvement to address deficiencies
identified during the baseline assessment, and health
worker training and follow-up support were provided.
Trained health care workers provided MPAC for 13 25
months, at which time this qualitative evaluation of the
program, utilizing in-depth interviews with program
participants, was completed.
This project was designed and implemented by Ipas, an
international non-governmental organization (NGO)
dedicated to ending preventable deaths and disabilities
from unsafe abortion, in partnership with local Ministries
of Health.
Setting
The study was conducted in the Rift Valley Province of
Kenya and the Kampala Province of Uganda. Health
facilities within these provinces were purposively selected
to participate based on demand for PAC, willingness of
providers and administrators to support implementation
of the pilot program, and availability of necessary
infrastructure for service provision. Although the selected
health facilities were not intended to be representative of
all facilities in the two countries, efforts were made to
include both public and private facilities, as well as those
operating at the primary, secondary, and tertiary care
levels. In Kenya, five public hospitals were included; in
Uganda, two public hospitals and 18 clinics belonging to
private midwives were included.
Baseline facility assessment
Prior to the implementation of MPAC, capacity of the
participating sites was evaluated utilizing a comprehen-
sive site assessment tool (30). This tool documented an
existing caseload for PAC services and evaluated support
for the program among staff and facility managers,
adequacy of infrastructure and equipment, human re-
sources capacity, and quality of care provided. As MPAC
was to be offered as an alternative to PAC with MVA, it
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both methods of treatment for incomplete abortion,
ensuring a choice of treatment for women; capacity to
provide PAC with both MVA and MPAC was strength-
ened as necessary.
Based on the initial assessment results, facilities in both
countries were upgraded to ensure adequate examination
rooms for PAC provision, locked cabinets for storage of
misoprostol, MVA equipment and post-treatment family
planning methods, and record books were introduced for
documentation of PAC cases. The process of registration
of misoprostol for PAC was initiated, protocols for
MPAC provision were developed and disseminated, and
training of MPAC providers was begun.
Program implementation
In both Kenya and Uganda, implementation of the
MPAC program was a multi-step process extending
over several years (Fig. 1). As an initial step, representa-
tives from both countries attended a 7-day regional
medical abortion and MPAC ‘Training of Trainers’
workshop in Tunisia in 2008. This workshop consisted
of values clarification exercises,
2 training in the provision
of medicines for uterine evacuation, and clinical site visits
to observe use of medical uterine evacuation in the health
care setting. Following this training, pilot programs to
introduce MPAC into Kenyan and Ugandan hospitals
and health centers were developed with the respective
countries’ Ministries of Health. Service delivery protocols
for provision of MPAC were developed for use in both
settings (Table 1). Participating sites’ facilities and
equipment were upgraded where necessary, and an initial
stock of commodities, including misoprostol, was pro-
cured for use in the pilot program.
In Uganda and Kenya, 51 and 22 health care workers
respectively were trained in provision of MPAC (see
Table 2). Individuals trained were a mix of obstetrician 
gynecologists, medical officers and midwives. The 5-day
training included values clarification, training in clinical
assessment of the client, use of misoprostol for PAC,
MVA for PAC, management of missed abortion and early
pregnancy failure, postabortion contraception, infection
prevention, management of complications, referral and
community involvement. After training, follow-up sup-
port continued in both countries. This support consisted
of follow-up phone calls every month for the first 3
months made by clinical trainers with additional training
and skills in supporting providers to launch and maintain
MPAC services, and a site visit 6 months after program
implementation. At these visits, records were reviewed
and case management was discussed.
Evaluation of MPAC implementation
Following implementation of MPAC programs in both
countries, an independent evaluation of the implementa-
tion process was conducted. In-depth qualitative inter-
views were conducted with MPAC service providers,
heads of the health care centers where MPAC had been
introduced, and local policymakers who had helped
establish MPAC services. Additionally, Ipas staff and
consultants who had been involved in the implementation
of MPAC were interviewed.
Four guides, tailored for each type of study participant,
were developed for the interviews; the same guides were
used in both countries. These guides contained open-
ended questions aimed at assessing strengths and weak-
nesses of the intervention, barriers and facilitating factors
encountered during implementation, providers’ satisfac-
tion with MPAC and providers’ impressions of patients’
satisfaction with MPAC. Participants were asked ques-
tions specific to their role in the program, as well as
general questions about the program and its implementa-
tion; data from all types of participants were compiled to
provide a summary evaluation of the program. In each
country, a single interviewer conducted interviews. Data
were collected between March and April 2010 in Kenya,
and from March to May 2011 in Uganda. A total of
45 interviews, 15 in Kenya and 30 in Uganda, were
completed (Table 3).
In addition to interviews, the evaluators reviewed
reports collected during program implementation, such
as site improvement reports, training assessment reports,
drug registration and procurement reports, and informa-
tion related to the availability of misoprostol. These
reports provided data related to the process of implemen-
tation of the program, such as numbers and types of
individuals trained, obstacles encounteredwhen establish-
ing services, and interim work plans. Routinely collected
program monitoring data were used to determine number
of women served by the project.
Management and analysis of evaluation data
In Kenya, interviews were recorded and fully or nearly
fully transcribed, while in Uganda, interview data was
largely captured via interviewer notes; only a small
number of interviews were recorded. Three investigators,
one in Uganda, one in Kenya, and one whoworked on the
evaluation in both countries, coded interview data utiliz-
ing a framework analysis plan developed prior to the
interviews, and reflected in the interview guides. This
framework asked participants to comment on the
strengths and weaknesses of the program and its imple-
mentation, including training and ongoing support,
2Values clarification exercises offer participants a safe space to
explore, question, clarify and affirm their values and beliefs about
abortion and related sexual and reproductive health issues. These
activities engage stakeholders to identify and address barriers to
abortion service provision, access and quality of care stemming from
misinformation, values conflict, negative attitudes and lack of
respect for women’s rights.
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of relevant stakeholders, sustainability of the program
and potential for scaling up. Additionally, participants
were questioned about any perceived changes in access to
PAC services, quality and acceptability of those services.
Differences between the two countries are noted; no
gender differences in responses of study participants
were noted. These data were supplemented with infor-
mation gleaned from the above-mentioned reports
documenting the program implementation, as well as
interviewer notes. In both countries, datawere collected to
the point of saturation, after which no new information
emerged during interviews (32). To ensure validity and
consistency across study sites and countries, an additional
investigator independently reviewed all coded data.
Results
Use of PAC services and women served by program
Service delivery data collected from sites at the 6-month
follow-up visit were used to estimate the number of
women served during the pilot projects (Table 4). In
Kenya, 222 women were served in 3 months, leading to an
estimated total of962 women served during the 13 months
between when the pilot began and when the evaluation
interviews were conducted. Of those, 47% (n 455) of
women received PAC with MVA and 53% (n 507)
received MPAC. In Uganda, 25 months elapsed between
the beginning of the pilot and conducting the interviews.
In that period of time, an estimated 5,467 women were
served in public facilities for the full 25 months and
private midwives served 949 women for 16 months.
The vast majority (87%, n 4,758) of women served in
public facilities received MPAC, compared with only 39%
(n 373) of women seen by private midwives.
Table 1. Clinical protocol for use of misoprostol in PAC (31)
Confirm diagnosis of incomplete or missed abortion:
k History consistent with incomplete or missed abortion
k Physical exam with gravid uterus of less than 12 weeks size
and an open cervical os with uterine bleeding (incomplete
abortion), or a closed cervical os and confirmation of
pregnancy loss by ultrasound (missed abortion)
Evaluate for conditions that require specialized or alternative
care:
k Contraindications to misoprostol including known allergy to
prostaglandins, confirmed or suspected ectopic
pregnancy, hemorrhagic disorder or concurrent
anticoagulant therapy
k If an intrauterine device is in place, removal of device prior
to administration of misoprostol
Counseling
k Emotional support
k Return to fertility, contraceptive counseling and provision of
contraceptives
k What to expect after using misoprostol
 Pain, bleeding and expulsion of pregnancy tissue
 Nausea, vomiting and diarrhea
 Fever, chills
k Discuss and provide pain management
k Review warning signs
 Excessive bleeding
 Signs of infection
 Failure of treatment
Administer misoprostol
k Misoprostol 600 mcg orally OR 400 mcg sublingually
k Administer pain medication simultaneously
k Let the client wait in facility for 30 min
k Re-administer if client vomits within 30 min
k Antibiotics may be used if history and physical are
suggestive of infection
k Where prevalence of Rhesus-negative status is high
and Rhesus immunoglobulin is available, Rhesus
immunoglobulin may be administered to Rhesus-
negative women
Follow-up
k Schedule a follow-up visit in 2 weeks
k Confirm completion of expulsion
 History: bleeding and cramping with passage of
clots and/or tissue
 Exam: uterus is normal size firm, and non-tender;
the adnexae are non-tender; cervical os is closed
k Review contraception
k Refer client for other services as needed
Table 2. Facilities and providers included in MPAC pilot
program
Kenya Uganda
Region Rift Valley Province Kampala Province
Public facilities 3 2
Private facilities 2 18
Providers trained 22 51
Table 3. Study participants in Kenya and Uganda
Respondents Kenya Uganda
Ministry of health 1 2
Ipas staff 2 2
Health facility managers
a 56
MPAC trainers 2 4
MPAC providers 5 16
Total 15 30
aHealth facility managers were also providers; they are reported
separately here.
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Enabling environment
In both Kenya and Uganda, the creation of an enabling
environment and stakeholder support of MPAC imple-
mentation were key to the success of the intervention.
Support from key officials in the Ministry of Health,
members of local medical boards and ethics committees,
and heads of the Obstetrics and Gynecology Depart-
ments in the implementing hospitals and clinics facili-
tated the implementation process and the success of
the program. Involving such individuals from the pro-
ject’s inception was helpful in ensuring their continued
support:
Our hospital administration were satisfied, and even
chose two people from the facility to attend the
training. Because they were involved, they have
supported us.
MPAC Provider, Kenya
Interviewees acknowledged that to move beyond the pilot
phase, broader stakeholder involvement, particularly of
international NGOs and multilateral organizations work-
ing in maternal health, would be advantageous to ensure
continued success of the program.
Commodity security
Commodity security presented initial and ongoing chal-
lenges in both settings. Initial stocks of misoprostol were
procured for use in the study in both countries. In Kenya,
however, the implementation of the program was delayed
while the drug was formally registered for obstetric and
gynecologic indications*a requirement of the Ministry
of Health before misoprostol could be used within the
confines of the program. Following this registration, local
pharmacists were trained in its clinical uses and in
properly referring women presenting with incomplete
abortion to health care facilities before the pharmacies
were supplied with misoprostol from the pharmaceutical
distributor. Underestimation of demand for the medica-
tion led to stock-outs of the drug within 3 months of
initiation of MPAC services, and failure of the involved
institutions to allocate a budget to purchase the medica-
tion delayed acquisition of misoprostol by approximately
1 month, during which time it was unavailable. In
Uganda, where misoprostol had previously been regis-
tered for use in treating postpartum hemorrhage,
Ministry of Health officials initially expressed concern
about ‘off-label’ use to treat incomplete abortion. Even-
tually, the Ministry of Health approved use of misopros-
tol for PAC within the confines of the program. However,
they did not develop a policy for sustained procurement,
leading the two Ugandan public health care facilities to
experience stock-outs of misoprostol within 1 month of
implementation. Stores of the medication intended for
use in postpartum hemorrhage were not allowed to be
re-allocated for MPAC:
The major challenge is for the Ministry of Health to
bring out a policy to address [misoprostol] usage as
one of the effective drugs... in maternal health care.
The National Medical Stores should stock the drug,
and hospitals and other facilities should have proper
records and requisition procedures for their stocks.
Ministry of Health Official, Uganda
Providers interviewed in both countries believed that a
formal agreement between program implementers and the
facilities where the protocol was implemented such as a
Memorandum of Understanding outlining a plan to
maintain supplies of misoprostol and delineating respon-
sibility for such maintenance, would have avoided the
observed stock-outs. The private UPMA facilities in
Uganda included in the pilot program received initial
stocks of misoprostol through the project and developed a
procurement plan for resupply, and did not experience the
commodity stock-outs observed in public facilities in both
Kenya and Uganda. At these facilities, the overarching
UPMA organization provided misoprostol to their mem-
ber facilities at a reasonable price. These funds were then
used to purchase additional supplies of misoprostol as
well as subsidize the operational costs of the organization.
Monthly training meetings provided a forum for health
care providers in the individual clinics to replenish their
misoprostol supplies.
Table 4. Estimated number of women served during the
pilot programs
Kenya Uganda
Number of women served 222 656   public facilities
in 3 months 178   private facilities
834   overall
Proportion served with 52% 87%   public facilities
misoprostol 39%   private facilities
77%   overall
Proportion served with MVA 47% 13%   public facilities
61%   private facilities
23%   overall
Number of women served 962 5,467   public facilities
during pilot* 949   private facilities
6,416   overall
*Kenya: using 3 months of service delivery data annualized to
cover 13 months of the intervention, from March 2009 through
March 2010; Uganda: using 3 months of service delivery data
annualized to cover 25 months of intervention in public facilities,
from February 2009 through March 2011 and 16 months of
intervention in private facilities, from November 2009 through
March 2011.
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Beyond ensuring commodity security, study participants
in both countries agreed that facility and staff require-
ments for provision of PAC were minimal. Public
facilities in both Kenya and Uganda had a higher volume
of patients requiring services than the private facilities
included in the pilot. In these busier settings, providers
recommended establishing two rooms for PAC provision,
and that each room be fitted with a lockable cupboard
in which to store medications and supplies and an
examination/procedure table; two rooms was considered
ideal to facilitate patient flow. In facilities with a
lighter caseload, one room was considered adequate for
counseling and performance of PAC with MVA or
misoprostol.
In busier facilities, participants estimated that a mini-
mum of one to two MPAC-trained providers should
be available at all times. Given frequent absences of
clinical staff, such as for continuing medical education
activities, and the need to allow for routine rotations
to other wards, staff days off, and day and night duties,
it was suggested that program managers consider these
varying schedules to ensure adequate presence of trained
providers. On-the-job training in MPAC and avoidance of
transfers or unnecessary rotation of trained staff to other
locations or departments were offered by study partici-
pants as two strategies to ensure sustainability of trained
staff. In smaller facilities with fewer cases, one provider
was adequate to meet patient demand.
Training
In both countries, study participants complimented the
training that they had received for MPAC. Follow-up
mentoring of trainees, via phone calls and in person,
provided support to new MPAC providers and was
valuable in ensuring high quality of care.
Provider perspectives of MPAC
Workload decompression
In both Kenya and Uganda, providers were very satisfied
with MPAC, and perceived that their clients were
similarly satisfied. Because the space and equipment
requirements for MPAC are minimal, and midlevel health
care providers in both countries were permitted to
provide MPAC, implementation of MPAC decompressed
the workload of PAC providers and decreased demand
for those health facility resources at higher levels in the
health care system, such as hospital beds, procedure
rooms/operating theaters, and MVA equipment, neces-
sary to provide PAC with MVA:
Previously, when it was MVA alone, some patients
used to stay here for one or two days waiting for
MVA because if you have only two or three MVA
kits, you have to do [the procedure], you process
the equipment ... sometimes we have a lot of
patients. ... . So [MPAC] has made it easier, more
accessible to the patients, and also to the providers.
Health facility manager and MPAC
provider, Kenya
It actually increased on the options for treatment
and was embraced by the health workers who were
prescribing misoprostol ...The fact that there was
reduced surgical intervention led to a reduction in
patient load and time of waiting.
MPAC provider, Uganda
Midlevel providers effectively administered MPAC, re-
porting decreased numbers of women awaiting treatment
with MVA, and freed skilled staff, including midwives, to
participate in other health care activities, particularly
those requiring a higher level of training. For those
providers trained in both MPAC and MVA, MPAC was
seen as easier and less time-intensive:
I am on night duty ...and it can be very busy ...
When I’m doing my rounds, I give [patients]
misoprostol and continue with other work ...
I cannot do the same with MVA–attend to other
patients at the same time. So, it is easier for me to
give the misoprostol than to do the MVA.
MPAC provider, Kenya
Benefits for patients
Providers stated that misoprostol appeared to be very
effective and associated with few complications. Providers
reported difficulty in getting women to return for a
recommended follow-up appointment after misoprostol
use; some attributed poor follow-up rates to MPAC’s
efficacy:
The drug is very effective ... on those with
incomplete abortion ... There are those who will
come back after a week, but most of them do not
usually come back to give us feedback ... . The ones
who have problems will always come back. That’s
why when they do not come back, we assume they
are well.
MPAC provider, Kenya
Providers believed MPAC caused women less discomfort
than PAC with MVA, and, as it does not necessitate
instrumentation of the uterus, that MPAC carried a lower
risk of postabortal infection. Oral administration of
misoprostol for PAC allowed women to avoid both a
procedure and admission to the hospital:
Since it gave them [clients] a viable and much less
painful method or option ... many of the clients
were satisfied. Many fear instrumentation requiring
taking them to the theatre, which sometimes re-
quires giving them anesthesia or some kind of
sedation. So all these would be avoided where you
use misoprostol.
MPAC provider, Uganda
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for women, both because the treatment itself is inexpen-
sive and because it avoided the additional expenses
associated with a surgical procedure and hospital admis-
sion. Avoiding an inpatient stay additionally offered
women greater confidentiality:
Abortion, including miscarriages, are much stigma-
tized in this country and also in the communities
where these women come from. So, when they are
given the drug and go home, nobody gets to know
the treatment they are getting. They don’t need to
worry about answering so many questions as to why
they have been admitted to the hospital.
Program staff, Kenya
However, in both countries, providers noted that a subset
of women, particularly younger women, preferred MVA
to misoprostol for PAC. They believed that these women
desired a more efficient treatment, and the knowledge
that their treatment was complete before leaving the
health facility and returning home. Some providers
themselves expressed concern with the uncertainty asso-
ciated with misoprostol use:
With misoprostol, you administer it but you are still
not very sure it will complete the abortion or the
woman will come back with prolonged bleeding ...
sometimes it doesn’t remove the products comple-
tely, so you end up again doing MVA ... MVA’s
advantage is that you are sure you have removed
[the products of conception] and the bleeding stops
instantly.
MPAC provider, Kenya
Supportive and inhibitive policies for
implementation of MPAC
Increased focus on maternal mortality
In both Kenya and Uganda, participants stated that a
desire to address maternal mortality due to unsafe
abortion opened the door to provision of MPAC. At
the time of the pilot, the Kenyan Ministry of Public
Health and Sanitation had officially adopted PAC as a
means to reduce maternal mortality; as such, strategies to
scale-up PAC, particularly cost-effective interventions
such as MPAC, were considered welcome additions.
Similarly, Uganda had prioritized maternal mortality in
its Road Map for Reduction of Maternal and Neonatal
Mortality (33) and its National Development Plan (34).
Importance of visible country support
Participants cited lack of country-based standards and
guidelines for MPAC in either Kenya or Uganda as a
challenge to implementation of MPAC services. Although
recommendations from WHO and NGOs were available,
study participants stated that national standards were
necessary, not only to provide a locally approved frame-
work for provision, but also to codify governmental
support for use of the technology. In Kenya, attempts to
include misoprostol in national guidelines for PAC had
met with resistance, despite its proven benefits. Govern-
ment ownership of MPAC programs, as evidenced by
integration into national policies, could facilitate scaling
up of successful pilot programs.
Registration status of misoprostol was an important
consideration in both settings. In Uganda, where mis-
oprostol was registered for postpartum hemorrhage at the
time of the program implementation, difficulties in
procurement of the drug specifically for use in MPAC,
outside of its registration, led to temporary stock-outs of
the medication within the program. An application for
registration of misoprostol for treatment of incomplete
abortion in Ugandawas approved after completion of the
pilot program. Broad registration of misoprostol in
Kenya was necessary and achieved before the Ministry
of Health approved the implementation of the MPAC
project in that country. Inclusion of misoprostol on
WHO’s List of Essential Medicines for labor induction
and medical abortion (35) at the time of program
development and implementation lent credibility to
proposals to utilize misoprostol for reproductive health
indications, despite the fact that misoprostol was not
added to the WHO list for incomplete abortion until 2009
(29). Soon after completion of the pilot program in
Kenya, misoprostol was added to the Kenyan Essential
Medicines List for management of incomplete abortion
(36).
Policies dedicated to MPAC, when implemented,
helped to facilitate dedication of health care resources
for ongoing MPAC training and supplies necessary to
maintain programs. Regardless of registration status of
misoprostol, lack of dedicated funding and a secure
supply chain for MPAC commodities led to stock-outs
of the medication during program implementation in
both countries. Reliance on donations of misoprostol, as
well as for other PAC commodities such as MVA kits,
impeded reliability and sustainability of these programs.
Discussion
Evaluation of this pilot MPAC program in two African
countries illustrates a number of facility factors and
policy inputs that facilitate the successful implementation
of MPAC services. To our knowledge, this is the first
study assessing the implementation of an MPAC program
outside of a clinical trial; these data can be used to inform
future MPAC programming efforts, both those being
newly established and those ready for scaling up. We
found that providers, health center administrators and
policy makers were very satisfied with the MPAC
program, and perceived that women receiving MPAC
services were satisfied as well. Earlier studies have
established the acceptability of MPAC to women for the
treatment of incomplete abortion (22, 23, 25, 26). Stated
benefits of the program for health care facilities included
Joachim Osur et al.
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with resultant workload decompression for those health
care workers providing MVA services; this sentiment was
expressed even though midlevel providers were trained to
offer both misoprostol and MVA for PAC in this project.
These findings echo those of a recent Nigerian study
assessing provider acceptability of MPAC (27). Further,
provision of routine PAC services, both MPAC and
MVA, by midlevel providers, freed those with a higher
level of training to attend to more complicated cases.
Respondents appreciated the decreased demand for
hospital resources, particularly for hospital beds, operat-
ing theatre/procedure room time, and equipment as a
result of MPAC implementation. Additionally, MPAC
providers believed that use of misoprostol offered women
greater privacy, reduced cost, and the option of a non-
invasive treatment for their incomplete abortion.
An enabling environment, with support from the
Ministry of Health and hospital administrators, was an
important precondition to establishing a successful
MPAC program. However, lack of national policies and
guidelines for MPAC created barriers to its implementa-
tion. Integration of MPAC into national health care
policies will both lend legitimacy to the use of misopros-
tol for PAC, and help to secure financial and other forms
of health systems supports for MPAC service provision.
The importance of governmental buy-in when expanding
abortion care in legally restricted settings has been
previously established (37).
Given the limited resources necessary for MPAC,
implementation of MPAC programs was seen as achiev-
able in many settings. Evaluation participants commen-
ted that adequate training in misoprostol use was
necessary for successful implementation, and that fol-
low-up support after training was helpful in ensuring
appropriate misoprostol provision and service quality, in
addition to providing support to health care providers
engaged in the MPAC program. A recent, large rando-
mized trial comparing MPAC to PAC with MVA in five
sub-Saharan African countries similarly recommends
adequate provider training with subsequent follow-up
and support as a means to reduce unnecessary interven-
tions while new providers become familiar with the
amount and duration of misoprostol side-effects, parti-
cularly bleeding (38). In those health care settings where
maintaining a pool of adequately trained providers, and
ensuring that trained providers were available at all times,
presented challenges, pre-service training, on-the-job
training, and minimizing loss of trained providers are
recommended.
In both Kenya and Uganda, procuring misoprostol
and maintaining adequate supplies of the drug was
difficult. Registration of misoprostol for the treatment
of incomplete abortion, accurately estimating demand for
misoprostol, and creating a formal plan to maintain
supplies of misoprostol with clearly delineated responsi-
bilities for such maintenance, were solutions proposed by
study respondents to prevent commodity stock-outs. In
Kenya, misoprostol was broadly registered for obstetric
and gynecologic indications as a precondition of program
implementation; in Uganda, misoprostol was registered
in 2011 for use in incomplete abortion as well as for other
indications (39) after the pilot program concluded. These
advances should facilitate future MPAC projects and
scaling up of this pilot program. In response to difficul-
ties in estimating misoprostol needs, Ipas has developed a
tool to assist health facilities in determining quantities of
medications, including misoprostol, that they will likely
need when implementing and maintaining MPAC and
medical abortion programs (40).
This pilot evaluation suffers from several limitations.
Importantly, as this study was designed as an evaluation
of the process of implementation of MPAC pilot pro-
grams in both Kenya and Uganda, baseline service
delivery data prior to implementation and client satisfac-
tion data from women receiving MPAC services were not
collected. Although baseline data were not collected,
MPAC was unavailable (outside of a research context)
prior to this pilot program in both countries. Studies
assessing women’s satisfaction with MPAC have been
previously published (22, 23, 25, 26); however, data
specific to the Kenya and Uganda settings may be helpful
in improving those countries’ services. Women were not
followed in this study, so we cannot substantiate provi-
ders’ views that women who did not return for follow-up
were satisfied with MPAC and had no need for additional
care. As the pilot was implemented in a limited number of
facilities that had shown in interest in providing MPAC
services and did not include a control group, the highly
positive attitude of our study participants toward the
program and MPAC in general may not be observed in
other facilities. Additionally, it is possible that social
desirability influenced the positive responses of the
participants, particularly given that values clarification
exercises were included in the program and that admin-
istrative support for the program was a requirement
for facility inclusion. We did not question participants
regarding their attitudes toward MPAC or incomplete
abortion in general, but gathered data related to program
implementation and provision of MPAC services. Due to
the design of the intervention, we did not assess access to
or use of misoprostol for PAC outside of formal health
facilities. Future projects and studies would ideally
incorporate community outreach workers, village health
workers, or pharmacy workers with regard to their
roles in increasing women’s access to PAC overall, and
misoprostol specifically.
Despite these limitations, valuable information was
gathered about the implementation of misoprostol for
PAC in these two low-resource settings. Information was
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and providers, leading to multiple layers of overlapping
information. This informative detail will be used to adapt
future introductions of misoprostol in varying settings.
Conclusion
Although MPAC is a simple, cost-effective and scientifi-
cally proven intervention, services are not available where
needed*as is the case in many parts of Africa. This
program evaluation highlights a number of facilitating
factors, such as an enabling environment, adequate
training and ongoing support of providers, ease of
provision of MPAC, and linking MPAC with maternal
mortality reduction goals, for the successful implementa-
tion of MPAC. We also identified several pitfalls to avoid,
such as failure to establish an ongoing plan for procuring
misoprostol, inadequate staffing of facilities with provi-
ders trained in MPAC, and failure to incorporate MPAC
into governmental policies, including registration of the
drug specifically for PAC. We hope this evaluation will
assist governments, NGOs, health care providers, and
others to effectively implement MPAC programs, and
ultimately save women’s lives.
Acknowledgements
The authors thank and acknowledge Dr. Isaac Mwanzo for his work
on this project in both Kenya and Uganda, Joyce Mulama for her
work on data collection and review in Kenya, Mosotho Gabriel for
her support to the design and implementation of the project, and
Nancy Nyaga for her technical assistance to the implementation of
MPAC in the countries. Other colleagues at the Ipas Africa Alliance
ofﬁce in Nairobi and among Ipas’ global and regional teams
provided support throughout the project and its evaluation. Finally,
we would like to thank all of the study participants, health center
staff and administrators, and Ministry of Health ofﬁcials who made
this project possible.
Conflict of interest and funding
None of the authors have any conflicts of interest to
disclose. This project and evaluation was made possible
in part by the generous support of Swedish International
Development Cooperation Agency (Sida), UKAid, and
other Ipas donors.
Contribution to authorship
JO participated in conceptualization of the evaluation,
supervised both evaluations, and reviewed the manu-
script. TB participated in conceptualization of the
evaluation, contributed to the discussion section, and
reviewed the manuscript. BL participated in conceptua-
lization of the evaluation, obtained IRB approval for
both evaluations, analyzed service delivery data and
reviewed the manuscript. DM collected and analyzed
study data, and reviewed the manuscript. EJ participated
in data validation and analysis, and drafting of the
manuscript. All authors provided final approval of this
manuscript.
Details of ethical and administrative approval
Ethical review and approval of the evaluation was
obtained from the Allendale Institutional Review Board
(USA). The Ministries of Health in Kenya and Uganda
approved the project.
References
1. Grimes DA. Unsafe abortion: the silent scourge. Br Med Bull
2003; 67: 99 113.
2. Singh S, Wulf D, Hussain R, Bankole A, Sedgh G. Abortion
worldwide: a decade of uneven progress. New York: Guttmacher
Institute; 2009.
3. Sedgh G, Singh S, Shah I, Ahman E, Henshaw S, Bankole A.
Induced abortion: incidence and trends worldwide from 1995 to
2008. Lancet 2012; 379: 625 32.
4. Kenya Penal Code. Sections 158 160, 214 and 240. Kenya; 1973.
5. Constitution of the Republic of Uganda. Part XIV(b), XX,
articles 22.2, 27, 34(3) and 41. Uganda; 1995.
6. Kenya Constitution. Chapter 4 part 2 Art. 26(4). Kenya; 2010.
Available from: http://www.kenyaembassy.com/pdfs/The%20
Constitution%20of%20Kenya.pdf [cited 19 April 2012].
7. World Health Organization (2010). Trends in maternal mortal-
ity: 1990 to 2008. Geneva: WHO Press.
8. World Health Organization (2011). Unsafe abortion. Global
and regional estimates of the incidence of unsafe abortion and
associated mortality in 2008. 6th ed. Geneva: WHO Press.
9. Center for Reproductive Rights (2010). In harm’s way: the
impact of Kenya’s restrictive abortion law. New York: Center for
Reproductive Rights.
10. Singh S. Hospital admissions resulting from unsafe abor-
tion: estimates from 13 developing countries. Lancet 2006;
368: 1887 92.
11. Postabortion Care Consortium Community Task Force (2002).
Essential elements of postabortion care: an expanded and
updated model. Postabortion Care Consortium.
12. World Health Organization (2012). Safe abortion: technical and
policy guidance for health systems. Geneva: WHO Press.
13. Raghavan S, Bynum J, eds. Misoprostol for treatment of
incomplete abortion: an introductory guidebook. New York:
Gynuity; 2009.
14. Hofmeyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol
for cervical ripening and induction of labor. Cochrane Database
Syst Rev 2010; Art. No.: CD000941. DOI: 10.1002/14651858.
CD000941.pub2.
15. Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins
for preventing postpartum haemorrhage. Cochrane Database
Syst Rev 2007; Art. No.: CD000494. DOI: 10.1002/14651858.
CD000494.pub3.
16. Kapp N, Lohr PA, Ngo TD, Hayes JL. Cervical preparation for
ﬁrst trimester surgical abortion. Cochrance Database Syst Rev
2010; Art. No.: CD007207. DOI: 10.1002/14651858.CD007207.
pub2.
17. Newmann SJ, Dalve-Endres A, Diedrich JT, Steinauer JE,
Meckstroth K, Drey EA. Cervical preparation for second
trimester dilation and evacuation. Cochrane Database Syst
Rev 2010; Art. No.: CD007310. DOI: 10.1002/14651858.CD007
310.pub2.
18. Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L,
Campana A. Medical methods for ﬁrst trimester abortion.
Joachim Osur et al.
10
(page number not for citation purpose)
Citation: Glob Health Action 2013, 6: 19649 - http://dx.doi.org/10.3402/gha.v6i0.19649Cochrane Database Syst Rev 2011; Art. No.: CD002855. DOI:
10.1002/14651858.CD002855.pub4.
19. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF,
Kapp N. Medical methods for mid-trimester termination of
pregnancy. Cochrane Database Syst Rev 2011; Art No.: CD
005216. DOI: 10.1002/14651858.CD005216.pub2.
20. Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical
treatments for incomplete miscarriage (less than 24 weeks).
Cochrane Database Syst Rev 2010; Art. No.: CD007223. DOI:
10.1002/14651858.CD007223.pub2.
21. Clark W, Shannon C, Winikoff B. Misoprostol for uterine
evacuation in induced abortion and pregnancy failure. Expet
Rev Obstet Gynecol 2007; 2: 67 108.
22. Shwekerela B, Kalumuna R, Kipingili R, Mashaka N,
Westheimer E, Clark W, et al. Misoprostol for treatment of
incomplete abortion at the regional hospital level: results from
Tanzania. BJOG 2007; 114: 1363 7.
23. Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher
J, et al. A randomized trial of oral misoprostol versus manual
vacuum aspiration for the treatment of incomplete abortion in
Kampala, Uganda. Obstet Gynecol 2005; 106: 540 7.
24. Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER,
Winikoff B. Alternatives to mifepristone for early medical
abortion. Int J Gynaecol Obstet 2007; 96: 212 8.
25. Bique C, Usta M, Debora B, Chong E, Westheimer E, Winikoff
B. Comparison of misoprostol and manual vacuum aspiration
for the treatment of incomplete abortion. Int J Gynaecol Obstet
2007; 98: 222 6.
26. Dao B, Blum J, Thieba B, Raghavan S, Ouedraego M,
Lankoande J, et al. Is misoprostol a safe, effective, acceptable
alternative to manual vacuum aspiration for post abortion care?
Results from a randomized trial in Burkina Faso, West Africa.
BJOG 2007; 114: 1368 75.
27. Dah T, Akiode A, Awah P, Fetters T, Okoh M, Ujah I, et al.
Introducing misoprostol for the treatment of incomplete abor-
tion in Nigeria. Afr J Reprod Health 2011; 15: 42 50.
28. World Health Organization (2011). WHO model list of essential
medicines. 17th List. Geneva: WHO Press.
29. World Health Organization (2009). WHO model list of essential
medicines. 16th List. Geneva: WHO Press.
30. Ipas (2003). Service delivery point assessment tool for initiation
of abortion related services. Chapel Hill: Ipas.
31. Ipas (2009). Misoprostol for management of incomplete and
missed abortions: a clinical protocol. Chapel Hill: Ipas.
32. Pope C, Ziebland S, Mays N. Analysing qualitative data. BMJ
2000; 320: 114.
33. Uganda Ministry of Health (2008). Road map for reduction
of maternal and neonatal death. Kampala, Uganda: Uganda
Ministry of Health.
34. Uganda (2010). National Development Plan. Kampala,
Uganda.
35. World Health Organization (2005). WHO model list of essential
medicines. 14th List. Geneva: WHO Press.
36. Ministry of Medical Services and Ministry of Public Health and
Sanitation (2010). Kenya essential medicines list 2010. Nairobi,
Kenya: Ministry of Medical Services and Ministry of Public
Health and Sanitation.
37. World Health Organization (2007). The WHO strategic ap-
proach to strengthening sexual and reproductive health policies
and programmes. Geneva: WHO Press.
38. Shochet T, Diop A, Gaye A, Nayama M, Sall AB, Bukola
F, et al. Sublingual misoprostol versus standard surgical care for
treatment of incomplete abortion in ﬁve sub-Saharan African
countries. BMC Pregnancy Childbirth 2012; 12: 127.
39. Uganda National Drug Authority (2011). Registration Number
6230/22/08: Misotac [Misoprostol 200mcg]. Kampala, Uganda:
Uganda National Drug Authority.
40. Ipas (2011). Medical abortion supply guidance, forecasting tool.
Chapel Hill: Ipas.
Implementation of misoprostol for PAC in Africa
Citation: Glob Health Action 2013, 6: 19649 - http://dx.doi.org/10.3402/gha.v6i0.19649 11
(page number not for citation purpose)